Wednesday, December 11, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

FDA Criticized for Working Too Closely With Biotech Company to Approve Alzheimer’s Drug

New findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find that the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The findings conclude that the regulator worked too closely with Biogen, despite significant concerns over the limited and side effects of the new drug Aduhelm.

If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.

One Response

  1. Conflicts of interest between the government and the pharmasuetical industrial complex?

    You don’t say…

    As lobbyists continue to outnumber representatives, redirecting your public funding at levels which most working people could not even begin to fathom.

    Your tax dollars, hard at work.

Leave a Reply

Your email address will not be published. Required fields are marked *

Search in Archive